20/20 Biolabs, Inc.: 5%+ holders

As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of 20/20 Biolabs, Inc. The largest reported stake is Jonathan M Cohen's, at 16.8%. 3 filings are on record since February 25, 2026 (Schedule 13D, March 10, 2026).

Streeterville Capital LLC also filed stake reports on 29 other companies ↓

Sell to companies like 20/20 Biolabs, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2026-03-10 · Holder: Jonathan M Cohen · Percent: 16.8% · SCHEDULE 13D
• Filed 2026-03-10 · Holder: Full Succeed International Limited · Percent: 6.3% · SCHEDULE 13G
• Event date 2026-02-25 · Holder: Streeterville Capital LLC · Percent: 9.9% · Shares: 543,680 · SCHEDULE 13G

20/20 Biolabs, Inc. has 3 Schedule 13D or 13G filings on record since 2026-02-25. 3 holders' latest filing reports 5% or more of common stock, par value $0.01. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind 20/20 Biolabs, Inc. and the warning signs.

See 20/20 Biolabs, Inc.'s free Snapshot Watch 20/20 Biolabs, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on 20/20 Biolabs, Inc. and the records around it.

20/20 Biolabs, Inc. elsewhere on the record

• IPO filing Apr 2026
• Crowdfunding filing Dec 2025
• Who owns it

Companies that share a holder

• Streeterville Capital LLC also filed stake reports on 29 other companies: Professional Diversity Network, Inc. (Oct 2026), Solowin Holdings, Ltd. (Oct 2026), Vivos Therapeutics, Inc. (Sep 2026)

Want the whole picture on 20/20 Biolabs, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on 20/20 Biolabs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on 20/20 Biolabs, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   15 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

Jonathan M Cohen

The securities held by the Reporting Person were acquired in connection with the transactions described in Item 3 above. The Reporting Person has made no plans or proposals which would be related to or would result in any of the events or matters described in part (a) through (j) of Item 4 above.Item 4 of the SCHEDULE 13D filed 2026-03-10

Timeline

Swipe the table sideways to see every column.

Questions about who owns 20/20 Biolabs, Inc.

Who owns 20/20 Biolabs, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of 20/20 Biolabs, Inc.: Jonathan M Cohen (16.8%, Schedule 13D, filed 2026-03-10), Streeterville Capital LLC (9.9%, Schedule 13G, filed 2026-02-25) and Full Succeed International Limited (6.3%, Schedule 13G, filed 2026-03-10).

Who are the largest shareholders of 20/20 Biolabs, Inc.?

By the share each holder's latest filing reports, the largest holders of 20/20 Biolabs, Inc. on this page are Jonathan M Cohen (16.8%), Streeterville Capital LLC (9.9%) and Full Succeed International Limited (6.3%).

When did Jonathan M Cohen buy into 20/20 Biolabs, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Jonathan M Cohen on this page is the Schedule 13D, filed 2026-03-10, reporting 16.8%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for 20/20 Biolabs, Inc.

Swipe the table sideways to see every column.

The newest 12 of 15 records.

Tools for this story

Each opens in a new tab, filled in for 20/20 Biolabs, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when 20/20 Biolabs, Inc. is mentioned again
• Find former 20/20 Biolabs, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes